fbpx
    • Life With Multiple Myeloma
    • Nov 22, 2017

    Mayo Clinic Shows Myeloma Expertise Matters for Long Term Outcomes

The Mayo Clinic performed a study to see whether treatment at centers with significant myeloma expertise mattered to myeloma patients’ long-term survival. In the recent publication in the Journal of Clinical Oncologythe investigators used the National Cancer Database to identify patients diagnosed with multiple myeloma between 2003 and 2011.

The patients were divided into quartiles of myeloma patients treated per year.

  • Q1 = facilities treating fewer than 3.6 patients per year
  • Q2 = facilities treating 3.6-6.1 patients per year
  • Q3 = facilities treating 6.1-10.3 patients per year
  • Q4 = facilities treating over 10.3 patients per year

The investigators then adjusted for clustering of patients within facilities, demographics (sex, age, race, ethinicity), socioeconomic (income, education, insurance type), geographic (area of residence, treatment facility location, travel distance), and comorbidity (Charlson-Deyo score) factors and year of diagnosis.

The distribution of patients was:

  • Q1 = 5.2%
  • Q2 = 12.6%
  • Q3 = 21.9%
  • Q4 = 60.3%

Overall survival numbers were then compared.

  • Q1 = 26.9 months
  • Q2 = 29.1 months
  • Q3 = 31.9 months
  • Q4 = 49.1 months

Even the difference between an entire facility (with multiple hematologists and oncologists) treating between 3 and 10 patients, overall survival was doubled. At a large myeloma center like MD Anderson, Dana Farber, Emory, Mayo Clinic or UAMS, the myeloma specialists are treating between 600 – 3,000+ cases per year. Myeloma experts understand the latest development in myeloma therapy and the nuances of personalized care. Because they specialize in myeloma, they can stay up-to-date on a cancer where accelerated, rapid-fire advances are occurring. For general oncologists, this is virtually impossible when trying to treat a wide range of cancers (prostate, breast, colon, etc.).

The study authors concluded:

Patients who were treated for MM at higher-volume facilities had a lower risk of mortality compared with those who were treated at lower-volume facilities.

Patients can successfully take advantage of both local care and myeloma expertise. Many patients will travel to consult with a myeloma expert who can give them treatment recommendations, strategy and craft a plan of attack. This plan can then be administered closer to home by a general oncologist. In this scenario, patients gain the expertise to extend their lives with the greatest convenience possible. You can find a myeloma specialist in our Myeloma Specialist Directory.

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

MYELOMA CROWD RESEARCH INITIATIVE
$162519 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: